Châtillon, France, May 30, 2024
DBV Technologies to Participate in Upcoming EAACI 2024 Congress
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage biopharmaceutical company focused on treatment options
for food allergies and other immunologic conditions with significant unmet
medical need, today announced its upcoming participation in the European Academy
of Allergy and Clinical Immunology (EAACI) Congress May 31 - June 3 in Valencia,
Spain.
A flash talk presentation by Nicolette Arends, M.D., Erasmus University
Rotterdam will describe data collected on accidental peanut consumption from
DBV's EPITOPE Phase 3 study and its ongoing open-label extension study in
peanut-allergic toddlers aged 1 through 3 years. DBV will also host a symposium
and exhibit booth in the EAACI exhibit hall.
"We are deeply committed to establishing long-term safety and clinical data of
Viaskin Peanut in the pediatric population, which includes examining reactions
that occur during accidental consumption," said Daniel Tassé, Chief Executive
Officer of DBV Technologies. "While avoidance is the first line of defense, the
reality is an accidental exposure is likely, necessitating approved treatment
options that can help provide protection."
"We track accidental peanut consumption in our clinical studies to better
understand how epicutaneous immunotherapy with Viaskin Peanut may help reduce
the risk of an allergic reaction over time," said Pharis Mohideen, M.D. Chief
Medical Officer at DBV Technologies. "Analyzing accidental peanut consumption
exposure better characterizes the real-world clinical benefit that Viaskin
Peanut may provide if approved."
DBV's symposium, "Epicutaneous Route: An Innovative Potential Approach to Food
Immunotherapy", will be moderated by Stefania Arasi, M.D., Ph.D., MSc.,
Pediatric Allergist and Researcher at Paediatric Allergy Unit, Bambino Gesù
Children Research Hospital, Rome, Italy and current EAACI Pediatric Section
Chair and Philippe Eigenmann, M.D., Pediatric Allergist and Head of Pediatric
Allergy Unit at the Geneva University Hospital, Geneva, Switzerland. It will
include lectures by Luciana Tanno, M.D., Ph.D. Allergist, Division of Allergy,
University Hospital of Montpellier, Montpellier, France on potential clinical
applications of the epicutaneous route, and Pablo Rodríguez del Río, M.D.,
Ph.D., Allergist Hospital Infantil Universitario Niño Jesús, Department of
Allergy, Madrid, Spain, on most recent results and perspectives of the
epicutaneous route in peanut allergy, respectively.
DBV will host a booth (F10) in the exhibit hall where attendees can learn more
about epicutaneous immunotherapy with Viaskin, including our ongoing clinical
trials in peanut-allergic children.
Flash Talk Presentation Details
"Reactions Due to Accidental Peanut Consumption During Epicutaneous
Immunotherapy for Peanut Allergy in Toddlers" presented by Nicolette Arends,
M.D. Researcher, Pediatrics Erasmus University Medical Center, Rotterdam,
Netherlands
* Session title: Flash Talks on Pediatrics
* Session number: FT 15
* Session date: Sunday, June 2, 2024
* Session time: 8:30 a.m. - 10:30 a.m. CET
A voice-recording of the onsite flash talk presentation will be made available
on the congress platform. A copy of the poster will be made available after the
presentation on the Scientific Publications & Presentations page on the Our
Science section of the Company's website www.dbv-technologies.com (https://dbv-
technologies.com/our-science/scientific-publications-and-presentations/).
Symposium
"Epicutaneous route: An innovative potential approach to food immunotherapy"
will be moderated by Stefania Arasi and Philippe Eigenmann
* Date and location: Saturday, June 1, 12:00 - 1:00 p.m. CEST, Malaga Room
* Lectures:
* Introduction- Dr. Stefania Arasi
* The epicutaneous route: from the concept to potential clinical
applications- Dr. Luciana Tanno
* The epicutaneous immunotherapy for peanut allergy: most recent results
and perspectives- Dr. Pablo Rodríguez del Río
* Conclusion- Dr. Philippe Eigenmann
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing
treatment options for food allergies and other immunologic conditions with
significant unmet medical need. DBV is currently focused on investigating the
use of its proprietary technology platform, Viaskin(TM), to address food allergies,
which are caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening anaphylaxis.
Millions of people live with food allergies, including young children. Through
epicutaneous immunotherapy (EPIT(TM)), the Viaskin platform is designed to
introduce microgram amounts of a biologically active compound to the immune
system through intact skin. EPIT is a new class of non-invasive treatment that
seeks to modify an individual's underlying allergy by re-educating the immune
system to become desensitized to allergen by leveraging the skin's immune
tolerizing properties. DBV is committed to transforming the care of food
allergic people. The Company's food allergy programs include ongoing clinical
trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age)
and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American
operations in Warren, NJ. The Company's ordinary shares are traded on segment B
of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs
(each representing one-half of one ordinary share) are traded on the Nasdaq
Stock Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com (http://www.dbv-
technologies.com/) and engage with us on X (formerly Twitter)
(https://twitter.com/DBVTechnologies) and LinkedIn
(https://www.linkedin.com/company/dbv-technologies/).
Forward Looking Statements
This press release may contain forward-looking statements and estimates,
including, but not limited to, statements regarding the therapeutic potential of
Viaskin(TM) Peanut and EPIT(TM) and DBV's planned regulatory and clinical efforts
including timing and results of communications with regulatory agencies, and the
ability of any of DBV's product candidates, if approved, to improve the lives of
patients with food allergies. These forward-looking statements and estimates are
not promises or guarantees and involve substantial risks and uncertainties. At
this stage, DBV's product candidates have not been authorized for sale in any
country. Among the factors that could cause actual results to differ materially
from those described or projected herein include uncertainties associated
generally with research and development, clinical trials and related regulatory
reviews and approvals, and DBV's ability to successfully execute on its budget
discipline measures. A further list and description of risks and uncertainties
that could cause actual results to differ materially from those set forth in the
forward-looking statements in this press release can be found in DBV's
regulatory filings with the French Autorité des Marchés Financiers ("AMF"),
DBV's filings and reports with the U.S. Securities and Exchange Commission
("SEC"), including in DBV's Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the SEC on March 7, 2024, and future filings and
reports made with the AMF and SEC by DBV. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements and
estimates, which speak only as of the date hereof. Other than as required by
applicable law, DBV Technologies undertakes no obligation to update or revise
the information contained in this Press Release.
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com (mailto:katie.matthews@dbv-technologies.com)
Media Contact
Angela Marcucci
DBV Technologies
angela.marucci@dbv-technologies.com (mailto:aurora.krause-ext@dbv-
technologies.com)
Â